Scantox
Scantox at a glance
Scantox is a leading European GLP-accredited contract research organisation (CRO) specialising in preclinical services that supports global pharmaceutical and biotech companies in their drug development process. Founded in 1977, Scantox has a proven track record of serving its trusted customers with services spanning from drug discovery leading into clinical trials. Acquired by Impilo in 2021 from Charles River, Scantox has experienced strong organic growth and expanded through six add-on acquisitions. In 2024, Scantox notably acquired QPS Neuro in Austria and Gentronix in Manchester, significantly expanding its value chain coverage.
Scantox facts
Specialist Pharma Services
January 2021
Lille Skensved, Denmark
Jeanet Løgsted (CEO)
Martin Amtoft (CFO)
Nicholas Hooge
Anna Ryrberg
Frederikke Beck
Johan Kårestedt
379
Investment thesis
- Large and fragmented pre-clinical CRO market with relatively high barriers to entry
- Ability to quickly re-emerge and strengthen position as a vital part of the Nordic and European pharma and biotech community
- Opportunity to expand service portfolio within both in-vivo toxicology and in-vitro/ADME services
- Opportunity to pursue add-on M&A within pre-clinical drug development and drug discovery
UN SDG Goals
Other portfolio companies
Oticon Medical
Oticon Medical is a global hearing healthcare company specializing in bone-anchored hearing solutions (BAHS), a niche segment addressing conductive hearing loss.
Qufora
Qufora is a fast-growing Danish medical technology product company with focus on transanal irrigation (“TAI”) products and collecting devices
Avia Pharma
Avia is a leading North European OTC/Rx platform